Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

Maju Mathews,1 Srihari Gopal,1 Isaac Nuamah,1 Ludger Hargarter,2 Adam J Savitz,1 Edward Kim,3 Wilson Tan,4 Bernardo Soares,5 Christoph U Correll6–81Department of Neuroscience, Janssen Research & Development, LLC, Raritan, NJ, USA; 2Department of Neuroscience, Janssen-Cilag EMEA, Ne...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Mathews M, Gopal S, Nuamah I, Hargarter L, Savitz AJ, Kim E, Tan W, Soares B, Correll CU
Format: article
Langue:EN
Publié: Dove Medical Press 2019
Sujets:
number-needed-to-harm
number-needed-to-treat
paliperidone palmitate 3-monthly
remission
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Accès en ligne:https://doaj.org/article/b81367fbed5e43a5b09a55d1a775e7bc
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/b81367fbed5e43a5b09a55d1a775e7bc

Documents similaires